This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Omeros’s 8K filing here.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Further Reading
- Five stocks we like better than Omeros
- Insider Trades May Not Tell You What You Think
- Micron Stock Under $100: Seize the AI-Driven Upside
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
